Despite the advent of new treatment strategies, many patients with diffuse large B-cell lymphoma (DLBCL) relapse or die of the disease. Prospective clinical trials have demonstrated that lenalidomide is an effective and safe treatment option, especially for non-germinal center B-cell (non-GCB) DLBCL. However, routine clinical data are lacking, which is why we provide the results of the so-far largest relapsed/refractory (R/R) DLBCL real-life analysis.
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
MONDELLO, PATRIZIA
Primo
;PITINI, Vincenzo;CUZZOCREA, SalvatorePenultimo
;
2016-01-01
Abstract
Despite the advent of new treatment strategies, many patients with diffuse large B-cell lymphoma (DLBCL) relapse or die of the disease. Prospective clinical trials have demonstrated that lenalidomide is an effective and safe treatment option, especially for non-germinal center B-cell (non-GCB) DLBCL. However, routine clinical data are lacking, which is why we provide the results of the so-far largest relapsed/refractory (R/R) DLBCL real-life analysis.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
The Oncologist-2016-Mondello-theoncologist.2016-0103.pdf
solo utenti autorizzati
Descrizione: Versione epub
Tipologia:
Versione Editoriale (PDF)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
743.93 kB
Formato
Adobe PDF
|
743.93 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
theoncologist.2016-0103.pdf
solo utenti autorizzati
Descrizione: Versione a stampa
Tipologia:
Versione Editoriale (PDF)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
732.67 kB
Formato
Adobe PDF
|
732.67 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
